These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

227 related articles for article (PubMed ID: 38332941)

  • 21. Estimated Reductions in Opioid Overdose Deaths With Sustainment of Public Health Interventions in 4 US States.
    Chhatwal J; Mueller PP; Chen Q; Kulkarni N; Adee M; Zarkin G; LaRochelle MR; Knudsen AB; Barbosa C
    JAMA Netw Open; 2023 Jun; 6(6):e2314925. PubMed ID: 37294571
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The impact of access to addiction specialist on attitudes, beliefs and hospital-based opioid use disorder related care: A survey of hospitalist physicians.
    Calcaterra SL; Binswanger IA; Edelman EJ; McNair BK; Wakeman SE; O'Connor PG
    Subst Abus; 2022; 43(1):143-151. PubMed ID: 32267807
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Ensuring buprenorphine access in rural community pharmacies to prevent overdoses.
    Ostrach B; Potter R; Wilson CG; Carpenter D
    J Am Pharm Assoc (2003); 2022; 62(2):588-597.e2. PubMed ID: 34674965
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Barriers and facilitators to nurse practitioner buprenorphine prescribing for opioid use disorder in primary care settings.
    Speight C; Caiola C; Tyndall DE; Scott ES
    J Am Assoc Nurse Pract; 2023 Feb; 35(2):112-121. PubMed ID: 36512806
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Medications for Opioid Use Disorder Do Help Patients.
    Nguyen KL; Forbriger J; Forbriger A; Schwarz ES
    Mo Med; 2022; 119(3):271-276. PubMed ID: 36035557
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Geographic and specialty distribution of US physicians trained to treat opioid use disorder.
    Rosenblatt RA; Andrilla CH; Catlin M; Larson EH
    Ann Fam Med; 2015; 13(1):23-6. PubMed ID: 25583888
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Modeling Mitigation Strategies to Reduce Opioid-Related Morbidity and Mortality in the US.
    Ballreich J; Mansour O; Hu E; Chingcuanco F; Pollack HA; Dowdy DW; Alexander GC
    JAMA Netw Open; 2020 Nov; 3(11):e2023677. PubMed ID: 33146732
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Naloxone provision to emergency department patients recognized as high-risk for opioid use disorder.
    Lane BH; Lyons MS; Stolz U; Ancona RM; Ryan RJ; Freiermuth CE
    Am J Emerg Med; 2021 Feb; 40():173-176. PubMed ID: 33243535
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clinical Trial Design Challenges and Opportunities for Emerging Treatments for Opioid Use Disorder: A Review.
    Kiluk BD; Kleykamp BA; Comer SD; Griffiths RR; Huhn AS; Johnson MW; Kampman KM; Pravetoni M; Preston KL; Vandrey R; Bergeria CL; Bogenschutz MP; Brown RT; Dunn KE; Dworkin RH; Finan PH; Hendricks PS; Houtsmuller EJ; Kosten TR; Lee DC; Levin FR; McRae-Clark A; Raison CL; Rasmussen K; Turk DC; Weiss RD; Strain EC
    JAMA Psychiatry; 2023 Jan; 80(1):84-92. PubMed ID: 36449315
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Looking beyond the opioid receptor: A desperate need for new treatments for opioid use disorder.
    Lee YK; Gold MS; Fuehrlein BS
    J Neurol Sci; 2022 Jan; 432():120094. PubMed ID: 34933249
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Medicaid Prescription Cap Policies: Another Structural Barrier to Medication for Opioid Use Disorder.
    Hughto JMW; Moyo P; Green TC
    J Addict Med; 2022 Nov-Dec 01; 16(6):616-618. PubMed ID: 35245915
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Trends and Characteristics of Buprenorphine-Involved Overdose Deaths Prior to and During the COVID-19 Pandemic.
    Tanz LJ; Jones CM; Davis NL; Compton WM; Baldwin GT; Han B; Volkow ND
    JAMA Netw Open; 2023 Jan; 6(1):e2251856. PubMed ID: 36662523
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Referral to and engagement in substance use disorder treatment within opioid intervention courts in New York: a qualitative study of implementation barriers and facilitators.
    O'Grady MA; Elkington KS; Robson G; Achebe IY; Williams AR; Cohall AT; Cohall R; Christofferson M; Garcia A; Ramsey KS; Lincourt P; Tross S
    Subst Abuse Treat Prev Policy; 2024 Jan; 19(1):12. PubMed ID: 38287329
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Developing an opioid use disorder treatment cascade: A review of quality measures.
    Williams AR; Nunes EV; Bisaga A; Pincus HA; Johnson KA; Campbell AN; Remien RH; Crystal S; Friedmann PD; Levin FR; Olfson M
    J Subst Abuse Treat; 2018 Aug; 91():57-68. PubMed ID: 29910015
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The impact of medical school education on the opioid overdose crisis with concurrent training in naloxone administration and MAT.
    Waskel EN; Antonio SC; Irio G; Campbell JL; Kramer J
    J Addict Dis; 2020; 38(3):380-383. PubMed ID: 32449488
    [TBL] [Abstract][Full Text] [Related]  

  • 36. METHADONE INITIATION IN THE EMERGENCY DEPARTMENT FOR OPIOID USE DISORDER: A CASE SERIES.
    Huo S; Heil J; Salzman MS; Carroll G; Haroz R
    J Emerg Med; 2023 Mar; 64(3):391-396. PubMed ID: 37019500
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Modelling the combined impact of interventions in averting deaths during a synthetic-opioid overdose epidemic.
    Irvine MA; Kuo M; Buxton JA; Balshaw R; Otterstatter M; Macdougall L; Milloy MJ; Bharmal A; Henry B; Tyndall M; Coombs D; Gilbert M
    Addiction; 2019 Sep; 114(9):1602-1613. PubMed ID: 31166621
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Comparison of neonatal outcomes in pregnant women undergoing medication-assisted treatment of opioid use disorder with methadone or buprenorphine/naloxone.
    Petrich M; Battin M; Walker E; Brown M; Abdelwahab M; Ma'ayeh M; Rood KM
    J Matern Fetal Neonatal Med; 2022 Dec; 35(26):10481-10486. PubMed ID: 36202398
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Has the treatment gap for opioid use disorder narrowed in the U.S.?: A yearly assessment from 2010 to 2019".
    Krawczyk N; Rivera BD; Jent V; Keyes KM; Jones CM; Cerdá M
    Int J Drug Policy; 2022 Dec; 110():103786. PubMed ID: 35934583
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Assessing Opioid Use Disorder Treatments in Trials Subject to Non-Adherence via a Functional Generalized Linear Mixed-Effects Model.
    St Ville M; Bergen AW; Baurley JW; Bible JD; McMahan CS
    Int J Environ Res Public Health; 2022 Apr; 19(9):. PubMed ID: 35564851
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.